Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

10-06-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: A nurse educator’s view of the REWIND trial

print
PRINT
insite
SEARCH

Nurse educator Lori Berard gives her view of how the REWIND trial can help clinicians working with people with type 2 diabetes (1:48).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

print
PRINT

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video

Related content

02-07-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

10-06-2019 | Dulaglutide | ADA 2019 | News

Dulaglutide cardioprotective in relatively low-risk REWIND population

10-06-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: The REWIND trial

17-10-2017 | GLP-1 agonists | At a glance | Article

Round up of the GLP-1 receptor agonist CV outcome trials
Image Credits